As per MRFR analysis, the India Thyroid Disorder Market Size was estimated at 96.4 (USD Million) in 2024.The India Thyroid Disorder Market Industry is expected to grow from 101.2(USD Million) in 2025 to 214.56 (USD Million) by 2035. The India Thyroid Disorder Market CAGR (growth rate) is expected to be around 7.071% during the forecast period (2025 - 2035).
The India Thyroid Disorder Market is experiencing significant growth driven by increasing awareness of thyroid diseases and the rising prevalence of related health issues. As lifestyles change, more people are adopting sedentary habits, which contribute to the rise in thyroid disorders. Government awareness campaigns and initiatives to promote health screenings have played a crucial role in educating the population about the importance of thyroid health, thereby boosting demand for diagnosis and treatment options. Additionally, the growing adoption of diagnostic tests, including blood tests for hormone levels, is providing patients and healthcare providers with better tools for early detection and management.
Opportunities in the market are also expanding as there is a rising focus on personalized medicine tailored to individual patient needs. New advancements in technology and research are paving the way for innovative treatment options, including biologics and gene therapies. The integration of telemedicine in healthcare is facilitating better access to specialists for remote consultations, especially in rural areas of India where healthcare facilities may be limited. Recent trends indicate that there is also a shift towards holistic treatment approaches, combining conventional medicine with lifestyle modifications and alternative therapies.
This trend reflects growing consumer interest in overall well-being as they seek comprehensive solutions to manage thyroid conditions.Research is increasingly highlighting the impact of diet and nutrition on thyroid health, resulting in a demand for supplements and dietary changes among patients. The combination of these drivers and trends suggests a dynamic landscape for the thyroid disorder market in India, with ample potential for growth and innovation.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Increasing Prevalence of Thyroid Disorders in India
The growing incidence of thyroid disorders in India is a significant driver for the India Thyroid Disorder Market Industry. Studies indicate that approximately 42 million people in India are affected by thyroid disorders, particularly hypothyroidism and hyperthyroidism. This rising prevalence can be attributed to various factors including lifestyle changes, dietary deficiencies, and increased stress levels among the Indian population. The Indian Council of Medical Research highlights that the cases of thyroid disorders are expected to rise further due to urbanization and changes in dietary habits, which is likely to spur the demand for diagnostic tests and treatment options in the India Thyroid Disorder Market Industry.
Additionally, with an increase in awareness regarding thyroid health, more individuals are seeking medical consultations, thereby positively affecting market growth. Enhanced screening initiatives have been promoted by government and health organizations, leading to earlier and more comprehensive diagnosis, which is imperative in addressing thyroid disorders effectively. As a result, the cumulative effect of these factors will potentially contribute to the growth trajectory of the India Thyroid Disorder Market Industry.
Growth in Healthcare Infrastructure and Diagnostic Facilities
The expansion of healthcare infrastructure and enhanced diagnostic facilities in India is a crucial factor driving the India Thyroid Disorder Market Industry. The Government of India has been actively investing in healthcare systems through initiatives like the National Health Mission, which aims to improve healthcare access and quality across the country. The establishment of new diagnostic centers and advancements in medical technology have led to an increase in the availability of accurate diagnostic tests for thyroid disorders.
As stated by the Ministry of Health and Family Welfare, healthcare expenditure in India will increase, subsequently giving rise to advanced diagnostic solutions. Better access to reliable tests will motivate people to get screened, which will subsequently boost the overall market for thyroid disorder diagnostics and treatments in the India Thyroid Disorder Market Industry.
Rising Awareness and Education about Thyroid Health
The increasing awareness of thyroid health among the Indian population is significantly driving the India Thyroid Disorder Market Industry. Various campaigns and initiatives launched by health organizations to educate the public about thyroid disorders have played a crucial role in this growth. The Thyroid Federation of India and other health NGOs are conducting workshops and seminars to raise awareness about symptoms, risk factors, and the importance of early detection.
Reports suggest that around 60% of people suffering from thyroid issues are unaware of their condition, indicating a large untapped market. The promotion of educational programs has led to more individuals seeking medical advice and timely diagnosis of thyroid disorders, which directly supports revenue growth in the India Thyroid Disorder Market Industry.
The India Thyroid Disorder Market demonstrates a diverse landscape shaped by various types of thyroid disorders, primarily focusing on Hypothyroidism and Hyperthyroidism. In India, Hypothyroidism is particularly prevalent, with a significant portion of the population suffering from this condition due to factors such as iodine deficiency, which has been a notable issue in various regions. This disorder is characterized by an underactive thyroid, leading to various health complications and the potential for increased healthcare costs, making its management a priority for patients and healthcare providers alike.
On the other hand, Hyperthyroidism, marked by an overactive thyroid gland, also presents significant challenges in the healthcare system. This condition can lead to a range of symptoms, including rapid heart rate, anxiety, and significant weight loss, requiring patients to seek immediate medical intervention. The increasing awareness and the rising incidence of thyroid disorders due to lifestyle changes and environmental factors are propelling the demand for effective diagnostic and therapeutic options in the country.
The India Thyroid Disorder Market segmentation reflects the critical need for targeted treatment approaches for both Hypothyroidism and Hyperthyroidism, which involve patient education and routine monitoring to ensure better health outcomes. Furthermore, the rising awareness of thyroid health is facilitating the growth of screening programs across India, thus contributing to the overall improvement in diagnosis rates. Increasing investment in Research and Development by pharmaceutical companies to develop advanced therapies and patient-centric treatment options further supports this market’s evolution.
Ultimately, as healthcare initiatives grow and more patients gain access to information on thyroid health, the focus on these types will intensify, ensuring better management of thyroid disorders and a larger impact on public health. The collective emphasis on both Hypothyroidism and Hyperthyroidism reflects their significant roles within the India Thyroid Disorder Market, with a sustained commitment to enhancing patient care and quality of life through medical advancements and effective healthcare policies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the India Thyroid Disorder Market plays a vital role in addressing the growing prevalence of thyroid conditions across the country. With an increasing awareness of thyroid health, the market has witnessed a systematic rise in demand for therapies that ensure effective management and care. Medications, primarily focused on hormone replacement and antithyroid drugs, are pivotal in regulating thyroid function and cater to a wider patient demographic. Radioactive Iodine Therapy is emerging as a significant option for hyperthyroidism treatment and thyroid cancer, providing a non-invasive approach that often leads to improved patient outcomes.
Meanwhile, Surgery remains a critical intervention for patients with large goiters or malignancies, where it provides definitive solutions that often lead to swift recovery. The diverse nature of treatment options across these areas reflects the necessity for tailored treatment approaches, aiding healthcare providers in delivering optimal care. The robust growth drivers for this segment include an aging population, urbanization, and increased healthcare access which reinforces the demand for effective treatment in the India Thyroid Disorder Market.
The Route of Administration segment is a crucial component of the India Thyroid Disorder Market, impacting how treatments are delivered to patients across the country. A significant portion of the market is attributed to oral administration, which is often preferred due to its convenience, ease of use, and patient compliance. This method allows patients to manage their thyroid conditions at home without the need for clinical supervision, thus enhancing adherence to treatment regimens. Intravenous administration, although less common, plays a vital role in severe cases where rapid drug action is required, often in clinical settings.
This method can provide immediate effects, making it particularly important for patients undergoing acute care. Other methods of administration also contribute to the market, catering to specific patient needs and preferences. The growing awareness about thyroid-related disorders and the increasing prevalence of these conditions in India drive the demand within this segment.
In addition, advancements in drug formulation and delivery methods present significant opportunities for innovation and market growth in the Indian healthcare landscape. The importance of the Route of Administration segment underscores its role in ensuring effective management of thyroid disorders, aligning with national health priorities to improve patient outcomes.
The India Thyroid Disorder Market has been witnessing significant growth, particularly in the End User segment where facilities such as hospitals and clinics play crucial roles in diagnosis and treatment. Hospitals are essential as they provide advanced medical technologies and comprehensive care for thyroid disorders, accommodating a large patient base. Clinics, on the other hand, offer accessible and cost-effective treatment options, ensuring early detection and management of thyroid-related issues. The increasing incidence of thyroid disorders in India, partially due to lifestyle changes and dietary habits, has led to heightened demand for these healthcare settings.
As more individuals seek thyroid testing and treatment, the importance of these End Users grows, with hospitals and clinics becoming pivotal in addressing health concerns. Furthermore, governmental initiatives aimed at enhancing healthcare infrastructure and services contribute to the development and expansion of the End User segment, facilitating better patient access to thyroid disorder management. Overall, the combination of increasing awareness, improved accessibility, and evolving healthcare policies drives the significant role of these End Users within the India Thyroid Disorder Market.
India Thyroid Disorder Market Key Players and Competitive Insights:
The India Thyroid Disorder Market is characterized by a growing awareness of thyroid health, leading to increased diagnosis and treatment of disorders such as hypothyroidism and hyperthyroidism. The market is influenced by various factors, including a rise in the prevalence of thyroid-related diseases, advancements in medical technology, ongoing research activities in endocrinology, and government initiatives to improve healthcare accessibility.
Competition in this market is driven by a mix of multinational corporations and domestic pharmaceutical companies, each striving to innovate and expand their product offerings. The competitive landscape is marked by a focus on quality, affordability, and availability of medications, leading to a diverse range of products aimed at addressing the specific needs of patients suffering from thyroid disorders.
Lupin operates with a solid presence in the India Thyroid Disorder Market, manifesting strengths such as a robust research and development pipeline and a wide range of high-quality generic medications. The company has established itself as a key player by offering effective thyroid medication that aligns with the needs of the Indian population. With a commitment to affordability, Lupin has made its products accessible to a diverse customer base, contributing to an increased market share. The firm emphasizes partnerships with healthcare professionals to better understand patient requirements, which has resulted in a trusted reputation within the medical community.
Additionally, Lupin's strategic marketing approaches help enhance brand recall, further solidifying its position in this therapeutic area.BristolMyers Squibb holds a vital role in the India Thyroid Disorder Market, bringing a legacy of innovation and commitment to patient care. The company offers a selection of thyroid medications designed to cater to the varying needs of patients, ensuring efficacy and safety. BristolMyers Squibb benefits from a well-structured distribution network in India, allowing for widespread accessibility to its products across urban and rural settings.
The company’s strengths lie in its focus on clinical research and continuous development, which enables it to stay ahead of industry changes and emerging patient needs. Strategic mergers and acquisitions in related healthcare sectors have allowed BristolMyers Squibb to enhance its market presence and leverage synergies, creating a competitive advantage while upholding the highest standards of quality. This stronghold in the market, coupled with a keen understanding of local healthcare dynamics, positions BristolMyers Squibb effectively within the thyroid disorder landscape in India.
Key Companies in the India Thyroid Disorder Market Include:
India Thyroid Disorder Market Industry Developments
In recent months, the India Thyroid Disorder Market has seen significant developments, including increased awareness and diagnosis rates among the population. Noteworthy is the growth of companies like Lupin, Sun Pharmaceutical, and Dr. Reddy's Laboratories, which have strengthened their portfolios in thyroid medications through Research and Development initiatives and strategic marketing campaigns. In July 2023, Sun Pharmaceutical expanded its distribution channels for its thyroid formulations, effectively reaching a larger patient base.
Additionally, the market has been influenced by an upturn in health awareness programs orchestrated by governmental health agencies, leading to an uptick in diagnosed cases of hypothyroidism and hyperthyroidism. In terms of mergers and acquisitions, there have been no notable announcements relating directly to major companies such as Pfizer, Merck, or GSK specifically within the thyroid segment in India. However, the overall valuation of the market is projected to grow, driven by the aging population and increasing prevalence of thyroid disorders. Furthermore, the emergence of telehealth services has facilitated better access to endocrinologists, fostering patient engagement and adherence to treatments.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 96.4(USD Million) |
| MARKET SIZE 2024 | 101.2(USD Million) |
| MARKET SIZE 2035 | 214.56(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.071% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Lupin, BristolMyers Squibb, GSK, Bayer, Dr. Reddy's Laboratories, Sun Pharmaceutical, Eli Lilly, Abbott, Roche, Merck, Sanofi, Mylan, AstraZeneca, Novartis, Pfizer |
| SEGMENTS COVERED | Type, Treatment, Route of Administration, End User |
| KEY MARKET OPPORTUNITIES | Increasing prevalence of thyroid disorders, Expansion of diagnostic services, Growth in telemedicine solutions, Rising awareness about thyroid health, Innovative treatment options and therapies |
| KEY MARKET DYNAMICS | Rising prevalence of thyroid disorders, Increased awareness and diagnosis, Aging population, Growth in healthcare spending, Advancements in treatment options |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Thyroid Disorder Market is expected to be valued at 101.2 million USD in 2024.
By 2035, the India Thyroid Disorder Market is projected to reach 214.56 million USD.
The expected CAGR for the India Thyroid Disorder Market from 2025 to 2035 is 7.071%.
The Hypothyroidism segment is anticipated to be the largest, valued at 55.0 million USD in 2024.
The Hyperthyroidism segment is expected to be valued at 98.56 million USD in 2035.
Key players include Lupin, BristolMyers Squibb, GSK, Bayer, and Dr. Reddy's Laboratories, among others.
Emerging trends include advancements in treatment options and increased awareness about thyroid disorders.
There are opportunities for growth due to rising prevalence of thyroid disorders and technological innovations.
The India Thyroid Disorder Market aligns with global health trends focusing on preventive healthcare and chronic disease management.
Challenges include the need for improved diagnosis and treatment accessibility across various regions.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
